Essential Biomaterials Science

This groundbreaking single-authored textbook equips students with everything they need to know to truly understand this hugely topical field, including essential background on the clinical necessity of biomaterials, relevant concepts in biology and materials science, comprehensive and up-to-date coverage of all existing clinical and experimental biomaterials, and the fundamental principles of biocompatibility. Drawing on the author's 40 years' experience in biomaterials, this is an indispensable resource for students of biomaterials science and engineering studying these life-saving technological advances.

Featuring

- A new classification system for biomaterials, a systematized framework for biocompatibility theory, new concepts for tissue engineering templates, and applications for nanomaterials in medicine.
- Extensive case studies from a wide range of clinical disciplines, interweaved with the theory, equipping students with a practical understanding of the phenomena and mechanisms of biomaterials performance.
- A whole chapter dedicated to the biomaterials industry itself, including guidance on regulations, standards and guidelines, litigation, and ethical issues, to prepare students for industry.
- Informative glossaries of key terms, engaging end-of-chapter exercises, and up-to-date lists of recommended reading.

David Williams is a Professor at the Wake Forest Institute for Regenerative Medicine, North Carolina, with over 40 years' experience in biomaterials science. He is Editor-in-Chief of the international journal *Biomaterials*, the President of the Tissue Engineering and Regenerative Medicine International Society, and a former Director of the UK Centre for Tissue Engineering at Liverpool University, where he is now an Emeritus Professor. In addition he is Advisory Professor of Shanghai Jiao Tong University, Visiting Chair Professor of Biomedical Materials, Taipei Medical University, a Visiting Professor of the Christiaan Barnard Department of Cardiothoracic Surgery, University of Cape Town, of the National University of Singapore, Tsinghua University, Beijing, Beihang University, Bejing, the University of New South Wales, Australia, and the Sree Chitra Tirunal Institute for Medical Science and Technology, Thiruvanthapuram, India. He has travelled extensively to promote excellence in scientific research and writing. He is a Fellow of the Royal Academy of Engineering, and has received numerous awards, including the 2012 Acta Biomaterialia Gold Medal.

> "This is the long overdue single-author compendium students, scientists and clinicians were waiting for. Anyone expecting a dry scientific compilation will be pleasantly surprised by the wonderfully lively style in which Prof. Williams takes the reader on an exciting journey into the world of modern biomaterials and the opportunities it offers to patients. In a field long plagued by self-sustained paradigms, wrong models and wrong questions, this book boldly introduces each chapter on the basis of true clinical needs, taking the captivated reader into the deepest depths of material science and biology and eventually leaving him in a position where his own understanding and judgment has undergone a quantum leap."

Peter Zilla

University of Cape Town, South Africa

"This revolutionary book provides a coherent synthesis of the entire field of biomaterials, from the underlying sciences, to its practical applications. The book is the culmination of thought from one of the leading pioneers in the field, David F. Williams, who has been active for over 45 years, and is able to bring together not only the importance of the subject matter, but also its historical perspective, and future trends. With a strategic focus of thought, this unique text is a seminal contribution that provides an invaluable and thorough resource for anyone interested in the biomaterials field, not just for students, but also for scientists, and government and industry personnel."

Anthony Atala

Wake Forest University School of Medicine, USA

"This book distils the wide-ranging field of biomaterials down to critical topics, and presents them in an accessible and user-friendly way. In writing the book, the author applies his innovative ideas, vast knowledge, and rich experience to adroitly tackle the challenge of 'less is more' in processing a wealth of subject matter, placing a special focus on dynamic interactions between various biomaterials with complex biological systems, and translation of tissue engineering products to the clinic. Another valuable feature of this book is the pedagogical implications contained in each topic, which begins with a clear, simple diagram to introduce the reader to the core information, and ends with a number of questions to help the reader to integrate basic concepts into practice. Accordingly, this book provides a great reference for graduate students, researchers, and doctors specializing in biomaterials science. Such empowerment will inevitably lead to advancing the state of the art in the field."

Xiaosong Gu Nantong University, China

"David Williams is one of the leading international authorities in biomaterials. Drawing on his vast multidisciplinary experience in the field, Prof. Williams presents in this attractive textbook not only a comprehensive view of biomaterials in their various facets, but also innovative ideas, along with the clarity of thought and precision of expression that those who know him well have come to expect of him. Although written primarily for students in biomaterials curricula, I see this book as 'a must' for the personal and institutional library."

> C. James Kirkpatrick Johannes Gutenberg University of Mainz, Germany

"This book provides the reader with the most up-to-date information on the ground-breaking revolutions in biomaterials sciences, and huge application potentials to overcome the most acute clinical challenges in the 21st-century. Reading this book is an academic enjoyment!" Yan Li

Zhongnan Hospital of Wuhan University, China

"It is a remarkable achievement for any one individual, even if that individual is David Williams, to construct such an accomplished and authoritative text. Based on a lifetime spent in the field, this book is comprehensive, thought-provoking, and forward-looking, and is beautifully written and illustrated. While intended, primarily, as a student text, it is certain that there will be biocompatibility between this work and academics, clinicians, regulators, and industry practitioners alike, and it is destined to become a definitive biomaterials science text." Keith McLean

CSIRO, Australia

"As the advancement of medical science cures various diseases, the role of biomaterials and their applications in medicine is recognized as growing. Almost every week, new biomaterials are announced and launched in the market. This book is composed of several chapters containing important information with many beautiful illustrations and photographs, which help students to understand biomaterials from very basic to near clinical applications. As one of the unique points of this book, each chapter has a brief glossary of biological and medical terms, which may be unfamiliar for students."

Teruo Okano

Tokyo Women's Medical University, Japan

"Williams' *Essential Biomaterials Science* combines comprehensive scope, single-authored consistency, and contemporary translational practicality in this novel textbook on biomaterials. The book clusters detailed considerations of materials, pathobiology, applications, regenerative therapeutics, and considerations of commercialization and clinical implementation, with an overriding focus on biocompatibility and concepts of biomaterial-tissue interactions, a key theme of Williams' many contributions to and leadership in this field. Well-illustrated, particularly with conceptual graphics, well-referenced with suggested readings, and with end-of-chapter questions, the book is most likely to be most useful to university students at an advanced undergraduate or graduate level, and nicely complements other available references in adding to the richness and usefulness of literature in the field." Frederick Schoen

Brigham and Women's Hospital, Harvard Medical School, USA

"This is an extraordinary, impressively thorough reference source and textbook. David Williams has a rare knack for clear communication. He draws on a unique combination of outstanding knowledge, remarkable experience, and a rare appreciation of the key concepts. This book is an absolutely essential, superbly comprehensive, and valuable resource for anyone who wants to truly understand the field of biomaterials."

Tony Weiss University of Sydney, Australia

Cambridge Texts in Biomedical Engineering

Series Editors W. Mark Saltzman, Yale University Shu Chien, University of California, San Diego

Series Advisors

Jerry Collins, Alabama A & M University Robert Malkin, Duke University Kathy Ferrara, University of California, Davis Nicholas Peppas, University of Texas, Austin Roger Kamm, Massachusetts Institute of Technology Masaaki Sato, Tohoku University, Japan Christine Schmidt, University of Florida George Truskey, Duke University Douglas Lauffenburger, Massachusetts Institute of Technology

Cambridge Texts in Biomedical Engineering provide a forum for high-quality textbooks targeted at undergraduate and graduate courses in biomedical engineering. It covers a broad range of biomedical engineering topics from introductory texts to advanced topics, including biomechanics, physiology, biomedical instrumentation, imaging, signals and systems, cell engineering, and bioinformatics, as well as other relevant subjects, with a blending of theory and practice. While aiming primarily at biomedical engineering students, this series is also suitable for courses in broader disciplines in engineering, the life sciences and medicine.

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

Essential Biomaterials Science

DAVID WILLIAMS

Wake Forest Institute for Regenerative Medicine



CAMBRIDGE UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning and research at the highest international levels of excellence.

www.cambridge.org Information on this title: www.cambridge.org/9780521899086

© David Williams 2014

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2014

Printing in the United Kingdom by TJ International Ltd. Padstow Cornwall

A catalog record for this publication is available from the British Library

Library of Congress Cataloging in Publication data Williams, D. F. (David Franklyn), author. Essential biomaterials science / David Williams. p. ; cm. – (Cambridge texts in biomedical engineering) Includes bibliographical references. ISBN 978-0-521-89908-6 (Hardback) I. Title. II. Series: Cambridge texts in biomedical engineering. [DNLM: 1. Biocompatible Materials. QT 37] R856 610.28-dc23 2013032183

ISBN 978-0-521-89908-6 Hardback

Additional resources for this publication at www.cambridge.org/biomaterialsscience

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information



Preface				page xvii
1	The	clinical r	necessity of biomaterials in the twenty-first century	1
	1.1		are products in medical practice	1
			ne ubiquitous low back pain	2
			porting injuries and arthritis	3
		-	ne end of the road for cataracts	6
		1.1.4 Tł	ie challenge of Parkinson's disease	6
			ne cath lab and beyond	8
		1.1.6 Pu	ulses and shocks in the heart	10
		1.1.7 Ca	are of the newborn	11
		1.1.8 Di	iagnosing and treating breast cancer	12
		1.1.9 Th	ne challenge of diabetes	13
		1.1.10 Tł	ne messy business of incontinence	15
	1.2	The ubique	uity of materials in clinical medicine	16
	1.3	The biom	aterials concept	17
	1.4	The evolu	ation of biomaterials science and the changing concepts	19
		1.4.1 Ea	rly implantable devices	19
		1.4.2 Th	e emergence of regenerative medicine	20
		1.4.3 Na	notechnology, diagnostics and drug delivery	21
		1.4.4 Th	e current definition of a biomaterial	22
	1.5	The class	ification of biomaterials applications	22
	1.6	The comp	ponents of biomaterials science	22
		•	arning objectives	26
	Quest	ions		27
	Recor	nmended re	eading	28
2	Esse	ential ma	terials science	29
		Introduct		29
	2.2	The basic	materials model	30
	2.3		olecules, interatomic and intermolecular bonds	38
			oms and the nature of elements	38
		2.3.2 Int	eractions between atoms	40
		2.3.3 Int	eractions between molecules	43
	2.4	The organ	nization of atoms and molecules: states of matter, crystalline a	nd
			us materials	44
		-	e states of matter	44
		2.4.2 Cr	ystallinity	44
		2.4.3 Ma	acro-, micro- and nano structures	51

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

viii Contents

2.5	Surfa	ce properties of materials	54
2.9	2.5.1	Surface energy: the hydrophilic/hydrophobic balance	54
	2.5.2	Surface chemistry	56
	2.5.3	Surface topography	60
	2.5.4	Techniques for surface modification	61
	2.5.5	Special considerations at the nanoscale	65
2.6		ical materials	65
		Metals and alloys	65
		Synthetic structural polymers, plastics, elastomers and textiles	68
		Biopolymers	72
		Ceramics, glasses and glass-ceramics	72
		Bioceramics	73
		Composites	73
		Natural composites	75
2.7		cal properties of materials	76
	2.7.1	Thermal properties	76
	2.7.2	Electrical properties	77
	2.7.3	Electronic and optoelectronic properties	78
	2.7.4	Magnetic properties	81
	2.7.5	Ultrasound	82
2.8	Mech	anical properties of materials	83
	2.8.1	Forces and stress: deformation and strain	83
	2.8.2	Elasticity and plasticity	85
	2.8.3	Fracture, ductility and toughness	88
	2.8.4	Time-dependent deformation: fatigue, creep and viscoelasticity	93
	2.8.5	Hardness	96
	2.8.6	Friction and wear	96
2.9	Corro	sion and degradation mechanisms	99
	2.9.1	Metallic corrosion	101
	2.9.2	Polymer degradation	106
	2.9.3	Ceramic degradation	110
	2.9.4	Performance of composites	112
2.10) Synth	esis, fabrication and manufacturing considerations	112
	2.10.1	Metallurgical processes	112
	2.10.2	Polymer processing	113
	2.10.3	Ceramic processing	114
	2.10.4	Composites	115
	2.10.5	Sterilization	115
2.11	l Enviro	onmental responsiveness	116
	2.11.1	Thermally responsive polymers	116
	2.11.2	pH responsive materials	118
	2.11.3	Shape memory materials	118
2.12	2 Specia	al considerations	119
	2.12.1	Nanoparticles as biomaterials	119

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

Contents (ix

	2.12.2	Injectable materials	122
	2.12.3	Self-assembly	123
	2.12.4	Biomimetic materials	123
Summ	nary and	l learning objectives	124
			125
Recor	nmende	d reading	126
Biod	compa	tibility pathways	129
3.1	Introd	uction	129
3.2	The fu	indamental biocompatibility paradigm	135
	3.2.1	Some general principles	138
	3.2.2	The components of biocompatibility	139
	3.2.3	A systems approach	140
3.3	Bioco	mpatibility scenarios	141
	3.3.1	Introduction to biocompatibility mechanisms and pathways	141
	3.3.2	Scenario A: Mechanisms of biocompatibility that do not rely on direct	
		chemical interactions between the biomaterial and the host	143
	3.3.3	Scenario B: Mechanisms of biocompatibility involving chemical	
		reactions between macroscale biomaterials and their soluble	
		derivatives with the host	161
	3.3.4	Scenario C: Mechanisms of biocompatibility involving microscale	
		biomaterials and microparticles	183
	3.3.5	Scenario D: Mechanisms of biocompatibility involving nanoscale	
		biomaterials	193
	3.3.6	Scenario E: Mechanisms of biocompatibility involving delivery of	
			200
3.4	Syster		208
	3.4.1		208
	3.4.2		210
	3.4.3	-	211
3.5			212
			212
			212
			215
3.6	-		216
		_	216
			218
			220
		-	222
3.7			223
			224
			224
		-	225
	3.7.4	Avoidance and treatment of bacterial infection	226
	Quest Recor 3.1 3.2 3.3	2.12.3 2.12.4 Sum v and Questions Recommender 3.1 Introd 3.2 The fu 3.2.1 3.2.2 3.2.3 3.3 Biocor 3.3.1 3.3.2 3.3.3 3.3 3.3 3.3 3.3 3.3	 2.12.4 Biomimetic materials Summary and learning objectives Questions Recommended reading Biocompatibility pathways 3.1 Introduction 3.2 The fundamental biocompatibility paradigm 3.2.1 Some general principles 3.2.2 The components of biocompatibility 3.2.3 A systems approach 3.3 Biocompatibility scenarios 3.3.1 Introduction to biocompatibility mechanisms and pathways 3.3.2 Scenario A: Mechanisms of biocompatibility involving chemical reactions between the biomaterial and the host 3.3.3 Scenario B: Mechanisms of biocompatibility involving chemical reactions between macroscale biomaterials and their soluble derivatives with the host 3.3.4 Scenario C: Mechanisms of biocompatibility involving microscale biomaterials 3.3.5 Scenario D: Mechanisms of biocompatibility involving microscale biomaterials 3.3.6 Scenario D: Mechanisms of biocompatibility involving delivery of pharmaceutical agents from macroscale biomaterials to host 3.4 Systemic or remote site biocompatibility 3.5.1 The generic biocompatibility 3.5.1 The generic biocompatibility 3.5.2 Target cells, defensive cells and interfering cells 3.5.3 Cellular mechanisms in biocompatibility pathways 3.5.3 Cellular mechanisms in biocompatibility phenomena 3.6.4 Nerve repair 3.7.1 Influences of bacteria, fungi, viruses, prions and endotoxins 3.7.1 Biofilms 3.7.2 Material variables and bacterial adhesion 3.7.3 Clinical aspects

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

x Contents

		3.7.5	Fungi	226
		3.7.6	Viruses	227
		3.7.7	Prions	227
		3.7.8	Endotoxins	227
	3.8	Clinic	cal and patient variables	227
		3.8.1	Clinical technique	228
		3.8.2	Patient variables	228
		3.8.3	General comments	228
	Sumn	nary and	d learning objectives	229
	Quest	tions		231
	Recor	nmende	ed reading	232
4	Imp	lantal	ble medical devices and artificial organs	236
	4.1		pedics	236
		4.1.1	-	238
		4.1.2	Ligaments and tendons	254
			The spinal column	255
			Bone defects	259
		4.1.5	Bone fracture	260
		4.1.6	Cartilage defects	262
	4.2	The c	ardiovascular system	263
		4.2.1	Arteries and veins	263
		4.2.2	Valves	271
		4.2.3	Congenital heart defects	279
		4.2.4	Myocardial infarction	280
		4.2.5	Arrhythmias	280
		4.2.6	Heart failure	283
	4.3	The n	najor organs: liver, kidney, lungs, pancreas	284
		4.3.1	The kidney: hemodialysis	285
		4.3.2	The lungs: extracorporeal membrane oxygenation	286
		4.3.3	The liver	286
		4.3.4	The pancreas: insulin pumps	287
	4.4	Eyes	and ears	287
		4.4.1	Contact lenses	287
		4.4.2	Intraocular lenses	288
		4.4.3	Glaucoma	289
		4.4.4	Retina and artificial vision	290
		4.4.5	External ear	291
		4.4.6	Middle ear	291
		4.4.7	Cochlear	292
	4.5	Centr	al nervous system	293
		4.5.1	Hydrocephalus shunts	294
		4.5.2	Deep brain stimulator	294
		4.5.3	Neural recording electrodes	295

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

Contents xi

	4.6	Genito	o-urinary system	296
		4.6.1	The bladder	296
		4.6.2	The overactive bladder in children	296
		4.6.3	Ureteral patency	296
		4.6.4	Urinary incontinence	297
		4.6.5	Pelvic organ prolapse	298
		4.6.6	Penile reconstruction	299
		4.6.7	Testicular implants	299
	4.7	Gastro	pintestinal system	299
		4.7.1	Gastric bands	299
		4.7.2	Anti-reflux devices	300
		4.7.3	Gastrointestinal stents	300
	4.8	Repro	ductive system	300
		4.8.1	Intravaginal devices	301
		4.8.2	Intrauterine devices	301
	4.9	Dentis	stry, maxillofacial and craniofacial tissues	301
		4.9.1	Oral cancer	301
		4.9.2	Dental implants	302
		4.9.3	Craniofacial reconstruction	302
	4.10	Genera	al soft tissue repair, replacement and augmentation	303
		4.10.1	Hernia	303
		4.10.2	Breast reconstruction	304
	4.11	306		
	Summary and learning objectives			306
	Quest	Questions		
	Recor	nmende	d reading	309
5	Reg	enerat	tive medicine and tissue engineering	313
	5.1		luction to regenerative medicine	313
	5.2		asic tissue engineering paradigms	315
	5.3		for tissue engineering	319
			Cell sources	319
		5.3.2	Principles of cell manipulation	331
		5.3.3		332
		5.3.4	Cell sheet engineering	332
	5.4	Biomo	blecules and nutrients for tissue engineering	334
		5.4.1	Culture media and oxygenation	335
		5.4.2	Growth factors	338
		5.4.3	Gene transfer in tissue engineering	339
	5.5	Bioma	aterials for regenerative medicine and tissue engineering	
		proces		340
		5.5.1	Background	340
		5.5.2	The concept of tissue engineering templates	341
		5.5.3	The objectives of tissue engineering templates	342

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

xii Contents

			Classification of tissue engineering templates	343
		5.5.5	1 1	344
			Specific types of template material	352
			Fluid mechanics and templates	360
			Fabrication routes for solid templates	362
			Bioprinting and organ printing	366
	5.6		engineering and clinical reality	367
			Bone tissue engineering	367
			Cartilage tissue engineering	369
			Skin tissue engineering	371
			Skeletal muscle tissue engineering	373
			Vascular tissue engineering	376
			Cardiac tissue engineering: the myocardium	378
			Cardiac tissue engineering: heart valves	382
			Nerve tissue engineering	383
			Urological tissue engineering	384
			Airway tissue engineering	386
	5.7		engineering of constructs for drug testing and tumor models	388
			l learning objectives	389
	Quest			390
	Recor	nmende	d reading	391
6	Dru	a and	aono delivery	202
0	6.1	-	gene delivery	393
	0.1			202
			uction to active molecule delivery	393
		6.1.1	Rationale for drug delivery technologies	394
	6.2	6.1.1 6.1.2	Rationale for drug delivery technologies Oral drug delivery	394 399
	6.2	6.1.1 6.1.2 Non-o	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs	394 399 400
	6.2	6.1.1 6.1.2 Non-c 6.2.1	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery	394 399 400 400
		6.1.1 6.1.2 Non-c 6.2.1 6.2.2	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems	394 399 400 400 404
	6.2 6.3	6.1.1 6.1.2 Non-c 6.2.1 6.2.2 Drug	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices	394 399 400 400 404 404
		6.1.1 6.1.2 Non-c 6.2.1 6.2.2 Drug 2 6.3.1	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release	394 399 400 400 404 404 404
	6.3	6.1.1 6.1.2 Non-c 6.2.1 6.2.2 Drug 2 6.3.1 6.3.2	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release	394 399 400 400 404 404 406 408
		6.1.1 6.1.2 Non-c 6.2.1 6.2.2 Drug 5 6.3.1 6.3.2 Drug 5	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems	394 399 400 400 404 404 404 406 408 409
	6.3	6.1.1 6.1.2 Non-o 6.2.1 6.2.2 Drug 2 6.3.1 6.3.2 Drug 2 6.4.1	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery	394 399 400 400 404 404 404 406 408 409 410
	6.3 6.4	6.1.1 6.1.2 Non-c 6.2.1 6.2.2 Drug 6.3.1 6.3.2 Drug 6.4.1 6.4.2	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery Nanoparticles and drug delivery	394 399 400 400 404 404 406 408 409 410 411
	6.3	6.1.1 6.1.2 Non-co 6.2.1 6.2.2 Drug 5 6.3.1 6.3.2 Drug 5 6.4.1 6.4.2 Polym	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery Nanoparticles and drug delivery ter therapeutics	394 399 400 400 404 404 404 406 408 409 410 411 415
	6.3 6.4	6.1.1 6.1.2 Non-co 6.2.1 6.2.2 Drug 2 6.3.1 6.3.2 Drug 2 6.4.1 6.4.2 Polym 6.5.1	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery Nanoparticles and drug delivery ere therapeutics Polymeric drugs	394 399 400 400 404 404 406 408 409 410 411 415 416
	6.3 6.4	6.1.1 6.1.2 Non-c 6.2.1 6.2.2 Drug 5 6.3.1 6.3.2 Drug 5 6.4.1 6.4.2 Polym 6.5.1 6.5.2	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery Nanoparticles and drug delivery ter therapeutics Polymeric drugs Polymer-active agent conjugates	394 399 400 400 404 404 406 408 409 410 411 415 416 417
	6.3 6.4 6.5	6.1.1 6.1.2 Non-c 6.2.1 6.2.2 Drug 6.3.1 6.3.2 Drug 6.4.1 6.4.2 Polym 6.5.1 6.5.2 6.5.3	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery Nanoparticles and drug delivery er therapeutics Polymeric drugs Polymer-active agent conjugates Polymer architecture	394 399 400 400 404 404 406 408 409 410 411 415 416 417 420
	6.3 6.4	6.1.1 6.1.2 Non-co 6.2.1 6.2.2 Drug : 6.3.1 6.3.2 Drug : 6.4.1 6.4.2 Polym 6.5.1 6.5.2 6.5.3 Cance	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery Nanoparticles and drug delivery er therapeutics Polymeric drugs Polymer-active agent conjugates Polymer architecture r: chemotherapy and immunotherapy	394 399 400 400 404 404 406 408 409 410 411 415 416 417 420 421
	6.3 6.4 6.5	6.1.1 6.1.2 Non-co 6.2.1 6.2.2 Drug 2 6.3.1 6.3.2 Drug 2 6.4.1 6.4.2 Polym 6.5.1 6.5.2 6.5.3 Cance 6.6.1	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery Nanoparticles and drug delivery er therapeutics Polymeric drugs Polymer-active agent conjugates Polymer architecture r: chemotherapy and immunotherapy Localized delivery of chemotherapeutic agents	394 399 400 404 404 404 406 408 409 410 411 415 416 417 420 421 421
	6.36.46.56.6	6.1.1 6.1.2 Non-c 6.2.1 6.2.2 Drug : 6.3.1 6.3.2 Drug : 6.4.1 6.4.2 Polym 6.5.1 6.5.2 6.5.3 Cance 6.6.1 6.6.2	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery Nanoparticles and drug delivery er therapeutics Polymeric drugs Polymer-active agent conjugates Polymer architecture r: chemotherapy and immunotherapy Localized delivery of chemotherapeutic agents Targeting chemotherapeutic agents to tumors	394 399 400 404 404 404 406 408 409 410 411 415 416 417 420 421 421
	6.3 6.4 6.5	6.1.1 6.1.2 Non-c 6.2.1 6.2.2 Drug : 6.3.1 6.3.2 Drug : 6.4.1 6.4.2 Polym 6.5.1 6.5.2 6.5.3 Cance 6.6.1 6.6.2	Rationale for drug delivery technologies Oral drug delivery oral delivery of conventional drugs Transdermal delivery Implantable electromechanical systems release from solid polymers in monolithic devices Mechanisms of release Solid polymers for drug release release from microparticulate and nanoparticulate systems Microparticles and drug delivery Nanoparticles and drug delivery er therapeutics Polymeric drugs Polymer-active agent conjugates Polymer architecture r: chemotherapy and immunotherapy Localized delivery of chemotherapeutic agents	394 399 400 404 404 404 406 408 409 410 411 415 416 417 420 421 421

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

Contents xiii

		6.7.2 Viral vectors	426
		6.7.3 Non-viral vectors	428
	6.8	Vaccines	434
	6.9	Antimicrobial agents	435
		6.9.1 Antibacterial agents and antibiotics	435
	6.10) Combinations of systems	439
		6.10.1 Theranostic agents	441
		6.10.2 Drug-device combinations	443
		nary and learning objectives	443
	Quest		444
	Recor	mmended reading	445
7	Ima	iging and diagnostic systems	448
	7.1	Introduction	448
		7.1.1 Anatomical and functional imaging	448
		7.1.2 Principles of molecular imaging	450
	7.2	Magnetic resonance imaging	451
		7.2.1 T1 agents	453
		7.2.2 T2 agents	453
		7.2.3 CEST and PARACEST	454
		7.2.4 ¹⁹ F agents	455
	7.3	CT imaging	455
	7.4	PET and SPECT imaging	456
	7.5	Ultrasound imaging	458
	7.6	Optical imaging	459
		7.6.1 Upconversion nanoparticles	460
		7.6.2 Quantum dots	463
	7.7	Multi-modal imaging	466
	7.8	Theranostics	466
	7.9	Biosensors	467
		7.9.1 The principles of sensing chemical and biological agents in tissu	les 467
		7.9.2 Enzyme-based biosensors	467
		7.9.3 Immunosensors	468
	7.10) General comments on nanoparticle toxicity in imaging systems	469
		7.10.1 Clinically observed effects	469
		7.10.2 Nanoparticle toxicity and biodistribution	470
		nary and learning objectives	470
	Quest		472
	Recor	mmended reading	473
8	Con	ntemporary and future biomaterials	475
	8.1	The classification of biomaterials	476
	8.2	Class 1 The metallic systems	477
		8.2.1 Class 1.1 Titanium and titanium alloys	477

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

xiv Contents

	8.2.2	Class 1.2 Iron and steels	481
	8.2.3	Class 1.3 Cobalt-based alloys	484
	8.2.4	Class 1.4 Nickel-based alloys	486
	8.2.5	Class 1.5 Tantalum and zirconium alloys	487
	8.2.6	Class 1.6 Silver	488
	8.2.7	Class 1.7 Platinum group metals and alloys	489
	8.2.8	Class 1.8 Gold	492
	8.2.9	Class 1.9 Magnesium and its alloys	493
8.3	Class	2 The ceramics systems	495
	8.3.1	Class 2.1 Oxides	497
	8.3.2	Class 2.2 Phosphates	505
	8.3.3	Class 2.3 Sulfates	507
	8.3.4	Class 2.4 Silicates and silica-based glasses	507
	8.3.5	Class 2.5 Nitrides	508
	8.3.6		508
	8.3.7	Class 2.7 Titanates	509
	8.3.8	Class 2.8 Optically active ceramic/metallic nanoparticles	510
8.4	Class	3 The polymeric systems	511
	8.4.1	Class 3.1 Thermoplastic polymers	515
	8.4.2	Class 3.2 Thermosetting resins	525
	8.4.3	Class 3.3 Synthetic polymeric sols and gels	525
	8.4.4	Class 3.4 Proteins and peptides	529
		Class 3.5 Polysaccharides	537
	8.4.6	Class 3.6 Lipids	542
	8.4.7		544
	8.4.8	Class 3.8 Water-soluble polymers	554
	8.4.9	Class 3.9 Polymers with ionizable or ionic groups	557
		Class 3.10 Elastomers	559
	8.4.11	Class 3.11 Fibers, fabrics and textiles	565
	8.4.11	Class 3.12 Environmentally responsive polymers	568
8.5		4 Carbon materials	568
		Class 4.1 Diamond and diamond-like materials	569
	8.5.2	Class 4.2 Graphitic materials	572
	8.5.3		573
	8.5.4	Class 4.4 Hexagonally bonded carbon nanostructures	573
8.6		5 Composite materials	575
	8.6.1	Class 5.1 Fiber reinforced thermoplastic polymers	576
	8.6.2	Class 5.2 Fiber reinforced resins	576
	8.6.3	Class 5.3 Ceramic microparticle reinforced biostable polymers	576
	8.6.4	Class 5.4 Ceramic microparticle reinforced biodegradable polymers	577
_	8.6.5	Class 5.5 Nanocomposites	577
8.7		6 Engineered biological materials	577
	8.7.1	General comments on tissue processing	578
	8.7.2	Class 6.1 Autologous tissues	580

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

9

Contents xv

8.7.3 Class 6.2 Allogencic tissues 580 8.7.4 Class 6.3 Xenogencic tissues 582 Summary and learning objectives 583 Questions 584 Recommended reading 585 Infrastructure of the biomaterials industry 590 9.1 Introduction 590 9.2 Principles of medical technology regulation 591 9.2.1 Risk assessment and risk management 592 9.2.2 Regulation in the USA 594 9.2.3 Regulation in the USA 599 9.3.1 Standards for the pre-clinical testing of biomaterials 603 9.4.1 Clinical trials of health care products 606 9.4.1 Clinical trials of health care products 606 9.4.2 Post-market surveillance 607 9.4.3 Implant registries 608 9.5 Product liability litigation in medical technology 609 9.5.2 Proplast and the temporomandibular joint 610 9.5.3 The Biox–Shiley heart valve 611 9.5.4 The Silcone breast implant story 612						
Summary and learning objectives583Questions584Recommended reading585Infræstructure of the biomaterials industry5909.1Introduction5909.2Principles of medical technology regulation5919.2.1Risk assessment and risk management5929.2.2Regulation in the USA5949.2.3Regulation in the USA5949.2.4Regulation in the VSA5949.2.3Regulation in the Asia-Pacific region5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4.1Clinical trials of health care products6069.4.1Clinical trials of health care products6069.4.2Post-market surveillance6069.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6119.5.5Silzone heart valve6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues622		8.7.3 Class 6.2 Allogeneic tissues	580			
Questions584Recommended reading585Infrastructure of the biomaterials industry5909.1Introduction5909.2Principles of medical technology regulation5919.2.1Risk assessment and risk management5929.2.2Regulation in the USA5949.2.3Regulation in the USA5989.2.4Regulation in the Asia-Pacific region5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials of health care products6069.4.1Clinical trials of health care products6069.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.7Intellectual property6199.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist		8.7.4 Class 6.3 Xenogeneic tissues	582			
Recommended reading585Infræstructure of the biomaterials industry5909.1Introduction5909.2Principles of medical technology regulation5919.2.1Risk assessment and risk management5929.2.2Regulation in the USA5949.2.3Regulation in the USA5949.2.4Regulation in the VSA5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials and post-market surveillance6069.4.1Clinical trials of health care products6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6119.5.3The Bjork-Shiley heart valve6119.5.4He silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6169.6.1Global inequalities in health and health care6159.6.2Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7 <t< td=""><td></td><td colspan="5"></td></t<>						
Infrastructure of the biomaterials industry5909.1Introduction5909.2Principles of medical technology regulation5919.2.1Risk assessment and risk management5929.2.2Regulation in the USA5949.2.3Regulation in the Asia-Pacific region5989.2.4Regulation in the Asia-Pacific region5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4.1Clinical trials of health care products6069.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.6.4Gotal and publishing6199.8.4Organ transplantation and organ assist6219.8.5Amit tissues6229.8.6Stem cells and human-derived products6239.8.7Commercializat			584			
9.1Introduction5909.2Principles of medical technology regulation5919.2.1Risk assessment and risk management5929.2.2Regulation in the USA5949.2.3Regulation in the Asia-Pacific region5989.2.4Regulation in the Asia-Pacific region5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials of health care products6069.4.1Clinical trials of health care products6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6119.5.3Silzone heart valve6139.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.7Intellectual property6179.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials624	Reco	mmended reading	585			
9.1Introduction5909.2Principles of medical technology regulation5919.2.1Risk assessment and risk management5929.2.2Regulation in the USA5949.2.3Regulation in the Asia-Pacific region5989.2.4Regulation in the Asia-Pacific region5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials of health care products6069.4.1Clinical trials of health care products6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6119.5.3Silzone heart valve6139.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.7Intellectual property6179.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials624	Infi	astructure of the biomaterials industry	590			
9.2 Principles of medical technology regulation 591 9.2.1 Risk assessment and risk management 592 9.2.2 Regulation in the USA 594 9.2.3 Regulation in the Norpe 598 9.2.4 Regulation in the Asia-Pacific region 599 9.3 Biomaterials and medical device standards and guidelines 603 9.4 Clinical trials of the pre-clinical testing of biomaterials 604 9.4 Clinical trials of health care products 606 9.4.1 Clinical trials of health care products 606 9.4.2 Post-market surveillance 607 9.4.3 Implant registries 608 9.5.1 The Dalkon Shield 609 9.5.2 Proplast and the temporomandibular joint 610 9.5.3 The Bjork-Shiley heart valve 611 9.5.4 The silicone breast implant story 612 9.5.5 Silzone heart valves 613 9.5.6 General observations 614 9.6.1 Global inequalities in health and health care 615 9.6.2 Medical technologies, cost-effectiveness and quality of		-				
9.2.1Risk assessment and risk management5929.2.2Regulation in the USA5949.2.3Regulation in Europe5989.2.4Regulation in the Asia-Pacific region5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials of health care products6069.4.1Clinical trials of health care products6069.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.7.1Intellectual property6179.8Ethical issues6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Marketing6259.8.10Orduct recalls625						
9.2.2Regulation in the USA5949.2.3Regulation in Europe5989.2.4Regulation in the Asia-Pacific region5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials and post-market surveillance6069.4.1Clinical trials of health care products6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6119.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.6.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.7Intellectual property6179.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6239.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Marketing6259.8.10Product recalls6259.8.11Off-label u	512					
9.2.3Regulation in Europe5989.2.4Regulation in the Asia-Pacific region5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials and post-market surveillance6069.4.1Clinical trials of health care products6079.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6239.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Marketing6259.8.10Product recalls6259.8.		_				
9.2.4Regulation in the Asia-Pacific region5999.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials and post-market surveillance6069.4.1Clinical trials of health care products6069.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6239.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10 <t< td=""><td></td><td>-</td><td></td></t<>		-				
9.3Biomaterials and medical device standards and guidelines6039.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials and post-market surveillance6069.4.1Clinical trials of health care products6069.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.7.1Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.3.1Standards for the pre-clinical testing of biomaterials6049.4Clinical trials and post-market surveillance6069.4.1Clinical trials of health care products6069.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual aproperty6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	9.3					
9.4Clinical trials and post-market surveillance6069.4.1Clinical trials of health care products6069.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6.1Global inequalities in health and health care6159.6.2Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	5.5	-				
9.4.1Clinical trials of health care products6069.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	94					
9.4.2Post-market surveillance6079.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6239.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	5.1	<u>~</u>				
9.4.3Implant registries6089.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork–Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6239.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625		-	000			
9.5Product liability litigation in medical technology6099.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.5.1The Dalkon Shield6099.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	95					
9.5.2Proplast and the temporomandibular joint6109.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6239.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	5.5					
9.5.3The Bjork-Shiley heart valve6119.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.5.4The silicone breast implant story6129.5.5Silzone heart valves6139.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.5.5Silzone heart valves6139.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.5.6General observations6149.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6239.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.6Health economics and social policy6149.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.6.1Global inequalities in health and health care6159.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	9.6					
9.6.2Medical technology as a driver of economy6169.6.3Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	510					
9.6.3Medical technologies, cost-effectiveness and quality of life6169.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625		-				
9.7Intellectual property6179.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.8Ethical issues6189.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	9.7					
9.8.1Research data and publishing6199.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.8.2Intellectual property6199.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625	510					
9.8.3Regulatory submissions6209.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.8.4Organ transplantation and organ assist6219.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.8.5Animal tissues6229.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.8.6Stem cells and human-derived products6239.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.8.7Commercialization of the human body6239.8.8Clinical trials6249.8.9Marketing6259.8.10Product recalls6259.8.11Off-label use625						
9.8.8 Clinical trials 624 9.8.9 Marketing 625 9.8.10 Product recalls 625 9.8.11 Off-label use 625		-				
9.8.9 Marketing 625 9.8.10 Product recalls 625 9.8.11 Off-label use 625		-				
9.8.10 Product recalls 625 9.8.11 Off-label use 625						
9.8.11 Off-label use 625		-				
		9.8.12 Re-use of single-use items	626			

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

 xvi
 Contents

 9.8.13
 Developing countries

 9.8.14
 The overall relationships between doctors/medical associations

 and industry
 627

 Summary and learning objectives
 628

 Questions
 629

 Recommended reading
 630

The colour plates are situated between pp. 396 and 397

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

PREFACE

Biomaterials are crucial components of many health care products. They are in the news daily as we hear of new devices that allow deaf people to hear, and of techniques to return patients to a near normal life after a heart attack. Headlines tell us of titanium dental implants, ceramic artificial hips, carbon heart valves, collagen cosmetic injections and clear plastic lenses in the eye. Science magazines talk of new drug–biomaterial combinations that are radically altering cancer chemotherapy and immunotherapy and of nanoscale contrast agents that give far more power to MRI and CT imaging systems for better and earlier disease diagnosis. Biomaterials save lives and improve the quality of life for millions of people.

The science that underpins these advances is, not surprisingly, called biomaterials science. It has grown and developed from tentative beginnings half a century ago into a major academic and clinical discipline today. This science is both multidisciplinary and interdisciplinary since it brings together many classical disciplines of science, engineering and medicine, but also adds new knowledge that fits within the gaps between the classical subjects.

Biomaterials science is one of the most attractive subjects in any curriculum and is taught in colleges and universities across the globe. Students of biomaterials science go on to become research scientists at the forefront of medical technologies, clinicians who actually use biomaterials-based products on a daily basis, industrialists who manufacture the products, regulators who decide what can and can't be used in clinical practice or a practitioner of any one of the other contributory professions. It is obvious that these students need a textbook to guide them through the complexities of the individual components that make up biomaterials science. That is the rationale for this book, *Essential Biomaterials Science*.

It will be evident from the above comments that the compilation of all of the essential features of biomaterials science in a single book is not a trivial task, since these essentials cover so many different themes. For this reason, most books on this subject are multi-author books, with individual contributions from many different scientists and clinicians, brought together by a panel of editors. *Essential Biomaterials Science* is different. It is the work of a single author. It brings together, with one style, the various components of biomaterials science and integrates them, hopefully with little repetition and few gaps, into a logical story. It covers the essential underlying sciences, both materials/engineering sciences and biological sciences, and the clinical applications.

I have spent over 40 years working in the area of biomaterials science, developing the understanding of the subject that allows such a book to be written. I wrote one of the first textbooks on biomaterials and medical devices in the early 1970s (Williams and Roaf, *Implants in Surgery*, W.B. Saunders) and my own research work, writing and teaching has covered many of the scientific areas that are discussed in this book. In addition I have been the Editor-in-Chief of the premier research journal in this field,

Cambridge University Press 978-0-521-89908-6 - Essential Biomaterials Science David Williams Frontmatter More information

Biomaterials, since 2001, a position that has allowed me to monitor and influence the developments on a global basis.

Essential Biomaterials Science is primarily intended as a textbook for students who are studying biomaterials at senior undergraduate and postgraduate levels. It should also serve as a reference source for anyone, at any level, who utilizes biomaterials in the course of their professional work. This especially includes those at post-doctoral or early faculty levels whose major disciplines have not been materials science, but also those in industry, regulatory or legal professions who regularly deal with health care products.

The book starts with an introduction to the world of biomaterials and medical devices served through a series of exemplars of current clinical practices that employ health care products routinely. Chapter 2 covers the essentials of materials science that underpin these clinical uses. In many ways Chapter 3 can be considered as the heart of the book since it deals with the mechanisms whereby the materials science and biology intersect, that is within the subject of biocompatibility; here a new unified framework of biocompatibility mechanisms is presented. Chapters 4 to 7 deal with the four main clinical applications, of implantable medical devices and artificial organs, tissue engineering and regenerative medicine, drug and gene delivery, and imaging and diagnostic systems. Chapter 8 comprehensively guides the reader through the array of current and potential biomaterials, with a new system for their classification. The final chapter discusses some of the infrastructure issues, including ethics, regulation and litigation.

In each chapter there are summaries of learning outcomes, glossaries, lists of recommended further reading and sample questions. The reading matter includes some other textbooks (marked *) but mainly provides citations to major review and opinion papers that take the reader more deeply into critical issues. All of these have been carefully chosen, mostly from the current literature and each citation includes a brief summary of the content of the work. Since this is a textbook, there are no references to support individual statements. I have also resisted the temptation to refer to commercial products and trade names since these are often ephemeral and become out-dated quickly. Occasionally a trade name becomes a generic descriptor and these are sparingly introduced. The glossaries are included in order to supply definitions of key individual terms, whose meanings may not be intuitively obvious.

The views expressed in this book mostly reflect my own beliefs, philosophies and prejudices and I therefore take full responsibility for the whole of the contents. Naturally I have been influenced by the writing and lectures of very many individuals, in many different countries and cultures. It is inappropriate to single out any such individuals here, but hopefully many of them will read or glance at this book and recognize where their thoughtful contributions have had an impact. Several of these colleagues have generously provided original artwork for illustrations; their collective support is gratefully acknowledged here and full credit is given to each in the relevant captions. I am very grateful to the staff at Cambridge University Press, especially Michelle Carey and Elizabeth Horne, for their guidance during the five years it has taken to prepare the book.

Preface xix

Most people who work in the area of biomaterials science will be aware that I have been supported in all of my endeavors by my wife, Peggy. Contributors to the journal *Biomaterials* will recognize her role, as Managing Editor of the journal, in coordinating much of the work that is published on this subject. Countless others have met her on our many biomaterials-related journeys around the world. Without her constant and unwavering support this book could not have been written. Too many days and nights have been spent, in North Carolina, South Africa and elsewhere, researching, writing and compiling the book, and her support, both practical and emotional, has been invaluable. My debt to Peggy is publicly acknowledged here.